Bio-Techne Statistics
Total Valuation
Bio-Techne has a market cap or net worth of $9.08 billion. The enterprise value is $9.33 billion.
| Market Cap | 9.08B |
| Enterprise Value | 9.33B |
Important Dates
The next estimated earnings date is Wednesday, February 4, 2026, before market open.
| Earnings Date | Feb 4, 2026 |
| Ex-Dividend Date | Nov 17, 2025 |
Share Statistics
Bio-Techne has 155.81 million shares outstanding. The number of shares has decreased by -1.27% in one year.
| Current Share Class | 155.81M |
| Shares Outstanding | 155.81M |
| Shares Change (YoY) | -1.27% |
| Shares Change (QoQ) | +0.39% |
| Owned by Insiders (%) | 1.12% |
| Owned by Institutions (%) | 105.48% |
| Float | 153.94M |
Valuation Ratios
The trailing PE ratio is 119.71 and the forward PE ratio is 28.83. Bio-Techne's PEG ratio is 2.52.
| PE Ratio | 119.71 |
| Forward PE | 28.83 |
| PS Ratio | 7.36 |
| Forward PS | 7.19 |
| PB Ratio | 4.52 |
| P/TBV Ratio | 14.26 |
| P/FCF Ratio | 40.52 |
| P/OCF Ratio | 36.14 |
| PEG Ratio | 2.52 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.68, with an EV/FCF ratio of 41.64.
| EV / Earnings | 119.68 |
| EV / Sales | 7.67 |
| EV / EBITDA | 28.68 |
| EV / EBIT | 35.45 |
| EV / FCF | 41.64 |
Financial Position
The company has a current ratio of 4.22, with a Debt / Equity ratio of 0.20.
| Current Ratio | 4.22 |
| Quick Ratio | 2.28 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | 1.13 |
| Debt / FCF | 1.76 |
| Interest Coverage | 28.40 |
Financial Efficiency
Return on equity (ROE) is 3.80% and return on invested capital (ROIC) is 6.72%.
| Return on Equity (ROE) | 3.80% |
| Return on Assets (ROA) | 6.25% |
| Return on Invested Capital (ROIC) | 6.72% |
| Return on Capital Employed (ROCE) | 11.05% |
| Revenue Per Employee | $392,494 |
| Profits Per Employee | $25,145 |
| Employee Count | 3,100 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 2.08 |
Taxes
In the past 12 months, Bio-Techne has paid $28.30 million in taxes.
| Income Tax | 28.30M |
| Effective Tax Rate | 26.63% |
Stock Price Statistics
The stock price has decreased by -18.40% in the last 52 weeks. The beta is 1.46, so Bio-Techne's price volatility has been higher than the market average.
| Beta (5Y) | 1.46 |
| 52-Week Price Change | -18.40% |
| 50-Day Moving Average | 60.97 |
| 200-Day Moving Average | 55.26 |
| Relative Strength Index (RSI) | 43.55 |
| Average Volume (20 Days) | 1,865,142 |
Short Selling Information
The latest short interest is 9.25 million, so 5.94% of the outstanding shares have been sold short.
| Short Interest | 9.25M |
| Short Previous Month | 9.27M |
| Short % of Shares Out | 5.94% |
| Short % of Float | 6.01% |
| Short Ratio (days to cover) | 4.57 |
Income Statement
In the last 12 months, Bio-Techne had revenue of $1.22 billion and earned $77.95 million in profits. Earnings per share was $0.49.
| Revenue | 1.22B |
| Gross Profit | 813.21M |
| Operating Income | 263.18M |
| Pretax Income | 106.28M |
| Net Income | 77.95M |
| EBITDA | 325.28M |
| EBIT | 263.18M |
| Earnings Per Share (EPS) | $0.49 |
Balance Sheet
The company has $144.96 million in cash and $394.47 million in debt, giving a net cash position of -$249.51 million or -$1.60 per share.
| Cash & Cash Equivalents | 144.96M |
| Total Debt | 394.47M |
| Net Cash | -249.51M |
| Net Cash Per Share | -$1.60 |
| Equity (Book Value) | 1.97B |
| Book Value Per Share | 12.62 |
| Working Capital | 464.96M |
Cash Flow
In the last 12 months, operating cash flow was $251.25 million and capital expenditures -$27.20 million, giving a free cash flow of $224.06 million.
| Operating Cash Flow | 251.25M |
| Capital Expenditures | -27.20M |
| Free Cash Flow | 224.06M |
| FCF Per Share | $1.44 |
Margins
Gross margin is 66.84%, with operating and profit margins of 21.63% and 6.41%.
| Gross Margin | 66.84% |
| Operating Margin | 21.63% |
| Pretax Margin | 8.74% |
| Profit Margin | 6.41% |
| EBITDA Margin | 26.73% |
| EBIT Margin | 21.63% |
| FCF Margin | 18.41% |
Dividends & Yields
This stock pays an annual dividend of $0.32, which amounts to a dividend yield of 0.55%.
| Dividend Per Share | $0.32 |
| Dividend Yield | 0.55% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 65.74% |
| Buyback Yield | 1.27% |
| Shareholder Yield | 1.82% |
| Earnings Yield | 0.86% |
| FCF Yield | 2.47% |
Analyst Forecast
The average price target for Bio-Techne is $71.23, which is 22.24% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $71.23 |
| Price Target Difference | 22.24% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (5Y) | 7.48% |
| EPS Growth Forecast (5Y) | 44.69% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 30, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Nov 30, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
Bio-Techne has an Altman Z-Score of 12 and a Piotroski F-Score of 6.
| Altman Z-Score | 12 |
| Piotroski F-Score | 6 |